Olfaction Disorders: Clinical Trials

2 trials for Olfaction Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Unknown 2
Phase 21Unknown 1

Follow Olfaction Disorders: new trials by email Literature Review of Olfaction Disorders trials Research Report on Olfaction Disorders

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia
Stellate Ganglion Block, Placebo - Parosmia
Phase 3UnknownLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's442024-02-152024-10-23
Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia
intranasal spray ivermectin - Anosmia
Phase 2 / Phase 3UnknownSouth Valley University1172021-04-202022-04-22

Narrower conditions

Anosmia (2)  ·  Post-Acute COVID-19 Syndrome (1)

Broader conditions

Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Sensation Disorders (2)  ·  Signs and Symptoms (2)  ·  COVID-19 (1)  ·  Chronic Disease (1)  ·  Coronaviridae Infections (1)  ·  Coronavirus Infections (1)  ·  Disease Attributes (1)  ·  Infections (1)  ·  Lung Diseases (1)  ·  Nidovirales Infections (1)  ·  Pathologic Processes (1)

Interventions

Autonomic Nerve Block (1)

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)  ·  South Valley University (1)

Countries

Canada (1)  ·  Egypt (1)

Results publications

PMID 15023839, PMID 23875929, PMID 33320115, PMID 33453291, PMID 34792577, PMID 34830550, PMID 34870334, PMID 35065619, PMID 35320821, PMID 35389456, PMID 36164334